Literature DB >> 23519539

Chemotherapy of vulvar cancer: a review.

Gunter Deppe1, Ismail Mert, Jimmy Belotte, Ira S Winer.   

Abstract

Squamous cell carcinoma of the vulva is a rare disease with good prognosis if diagnosed early. The standard primary therapy is surgery. Neoadjuvant radiation or chemotherapy has been used to achieve resectability of the tumor and to decrease the radicality of the surgery. Chemotherapy with platinum compounds, paclitaxel and targeted therapy (erlotinib) has shown activity. International collaborative trials are needed to identify the best therapeutic strategy for patients with squamous cell cancer of the vulva who are not candidates for primary surgery or concomitant chemoradiation. We review the various treatment options available to patients with advanced or recurrent squamous cell cancer of the vulva.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519539     DOI: 10.1007/s00508-013-0338-y

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  83 in total

Review 1.  Potential advantages of intensity-modulated radiation therapy in gynecologic malignancies.

Authors:  Anuja Jhingran
Journal:  Semin Radiat Oncol       Date:  2006-07       Impact factor: 5.934

2.  Concomitant radiation therapy and chemotherapy in the treatment of advanced squamous carcinoma of the lower female genital tract.

Authors:  W S Roberts; J J Kavanagh; H Greenberg; S C Bryson; J P LaPolla; P A Townsend; M S Hoffman; D Cavanagh; S Hewitt
Journal:  Gynecol Oncol       Date:  1989-08       Impact factor: 5.482

3.  Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study.

Authors:  J T Thigpen; J A Blessing; H D Homesley; G C Lewis
Journal:  Gynecol Oncol       Date:  1986-03       Impact factor: 5.482

4.  Treatment of advanced carcinoma of the vulva with chemoradiotherapy - can exenterative surgery be avoided?

Authors:  D.J. Sebag-Montefiore; C. McLean; S.J. Arnott; P. Blake; P. Van Dam; C.N. Hudson; J.H. Shepherd
Journal:  Int J Gynecol Cancer       Date:  1994-05       Impact factor: 3.437

5.  Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer.

Authors:  Sileny N Han; Ignace Vergote; Frédéric Amant
Journal:  Int J Gynecol Cancer       Date:  2012-06       Impact factor: 3.437

6.  Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva.

Authors:  S C Han; D H Kim; S A Higgins; M L Carcangiu; B M Kacinski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

7.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

8.  Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  Bradley J Monk; Michael W Sill; Robert A Burger; Heidi J Gray; Thomas E Buekers; Lynda D Roman
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study.

Authors:  Alejandro M Aragona; Nicasio Cuneo; Alejandro H Soderini; Elsa Alcoba; Adriana Greco; Carlos Reyes; Silvia Lekmann
Journal:  Int J Gynecol Cancer       Date:  2012-09       Impact factor: 3.437

10.  Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina.

Authors:  A Berchuck; G Rodriguez; A Kamel; J T Soper; D L Clarke-Pearson; R C Bast
Journal:  Obstet Gynecol       Date:  1990-09       Impact factor: 7.661

View more
  4 in total

1.  What to do when nothing else is left to be done - metastatic non-HPV vulvar squamous cell carcinoma with multiple lines of chemotherapy.

Authors:  Mihaela Mărioara Stana; Sandra Deac; Călin Cainap; Patriciu Achimaș-Cadariu; Mădălina Bota; Liliana Resiga; Dan Ștefan Luchian; Ovidiu Vasile Bochiș
Journal:  Arch Clin Cases       Date:  2021-12-29

2.  Nursing of Vulvar Cancer Radical Operation Combined with Laparoscopic Inguinal Lymph Node Dissection.

Authors:  Simei Huang; Feifei Qiu
Journal:  Emerg Med Int       Date:  2022-09-05       Impact factor: 1.621

3.  Recommendations for the treatment of vulvar cancer in settings with limited resources: Report from the International Gynecological Cancer Society consensus meeting.

Authors:  Fernando Cotait Maluf; Graziela Dal Molin Zibetti; Eduardo Paulino; Andreia Cristina de Melo; Douglas Racy; Robson Ferrigno; Pedro Luiz Serrano Uson Junior; Reitan Ribeiro; Renato Moretti; Jose Carlos Sadalla; Angelica Nogueira Rodrigues; Filomena Marino Carvalho; Glauco Baiocchi; Donato Callegaro-Filho; Roberto Angioli
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

Review 4.  Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology.

Authors:  Pavol Zubor; Yun Wang; Alena Liskova; Marek Samec; Lenka Koklesova; Zuzana Dankova; Anne Dørum; Karol Kajo; Dana Dvorska; Vincent Lucansky; Bibiana Malicherova; Ivana Kasubova; Jan Bujnak; Milos Mlyncek; Carlos Alberto Dussan; Peter Kubatka; Dietrich Büsselberg; Olga Golubnitschaja
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.